Study of STM-416p for Prostate Cancer
This study is looking at STM-416p, an immunotherapy and targeted therapy, in men with prostate cancer who are having surgery to remove their prostate (radical prostatectomy). Researchers want to see how safe STM-416p is and what side effects it might cause. They will track side effects for up to 90 days. You might be able to join if you are a man aged 18 or older with prostate cancer, are scheduled for a radical prostatectomy within 28 days, and meet certain health requirements. The study plans to include 18 participants. The current status of the study is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It is a dose escalation study, which means different groups of participants will receive increasing doses of STM-416p.
- What's involved
- You would receive STM-416p during your prostatectomy surgery. Safety will be checked for 21 days for dose-limiting toxicities and up to 90 days for other side effects.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your safety will be monitored for up to 90 days after starting the trial.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
At a glance
Conditions
Where it's being run
4 sites across 3 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Incidence of dose-limiting toxicities (DLTs) [Safety and Tolerability]21 Days
Incidence of dose-limiting toxicities (DLTs) over the first 21-days of study treatment
- Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time on trial up to 90 days
Incidence of serious adverse events (SAEs), and adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0